Lung-MAP aims for faster, more precise trials
This article was originally published in Scrip
Executive Summary
A much anticipated trial being run under a public-private partnership involving the US National Cancer Institute (NCI), five drug makers and a group of nonprofits using a "master protocol" approach finally for got underway on 16 June, with the goal of matching the most appropriate experimental drug to the right patient, which ultimately would improve and accelerate the clinical testing process, speeding new targeted medicines to the marketplace.